Nuvalent Files 8-K for Other Events
Ticker: NUVL · Form: 8-K · Filed: Sep 22, 2025 · CIK: 1861560
Sentiment: neutral
Topics: 8-k, regulatory-filing
Related Tickers: NUVAL
TL;DR
Nuvalent filed an 8-K for 'Other Events' - details TBD.
AI Summary
Nuvalent, Inc. filed an 8-K on September 22, 2025, to report other events. The filing does not contain specific details about the nature of these events, dollar amounts, or new agreements.
Why It Matters
This filing indicates Nuvalent has reported an event not covered by other standard 8-K items, requiring further investigation into the nature of the event.
Risk Assessment
Risk Level: medium — The filing is an 8-K for 'Other Events,' which is broad and could encompass significant developments not immediately apparent.
Key Players & Entities
- Nuvalent, Inc. (company) — Registrant
- 0001861560 (company) — Central Index Key
- 001-40671 (company) — SEC File Number
FAQ
What specific event(s) are being reported under 'Other Events' in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported.
When was this 8-K filing submitted to the SEC?
The filing was submitted on September 22, 2025.
What is Nuvalent, Inc.'s principal executive office address?
Nuvalent, Inc.'s principal executive offices are located at One Broadway, 14th Floor, Cambridge, Massachusetts 02142.
What is Nuvalent, Inc.'s telephone number?
Nuvalent, Inc.'s telephone number is (857) 357-7000.
What is the SIC code for Nuvalent, Inc.?
The Standard Industrial Classification (SIC) code for Nuvalent, Inc. is 2834 (Pharmaceutical Preparations).
Filing Stats: 400 words · 2 min read · ~1 pages · Grade level 9.6 · Accepted 2025-09-22 06:30:38
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share NUVL The Nasdaq
Filing Documents
- nuvl-20250922.htm (8-K) — 40KB
- 0001193125-25-209934.txt ( ) — 143KB
- nuvl-20250922.xsd (EX-101.SCH) — 25KB
- nuvl-20250922_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On September 22, 2025, Nuvalent, Inc. announced the completion of its New Drug Application submission to the U.S. Food and Drug Administration for zidesamtinib in tyrosine kinase inhibitor pre-treated patients with advanced ROS1-positive non-small cell lung cancer.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvalent, Inc. Date: September 22, 2025 By: /s/ Deborah A. Miller, Ph.D. Deborah A. Miller, Ph.D. Chief Legal Officer and Secretary